Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant α-2b interferon and doxorubicin: Results of a pilot study

Lotz, Jean‐Pierre; Grangé, Jean‐Didier; Hannoun, L.; Boudghene, F; Lamarque, Dominique; Thewis, André; Esteso, A.; Bellaïche, Annie; Bouleuc, Carole; Bodin, F; Parc, R; Bigot, Jean-Michel; Izrael, V.

doi:10.1016/0959-8049(94)90181-3

Cited by 5 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toxicity was generally tolerable, with fever, fatigue, and myelosuppression being the most common side effects. The same approach was used by Lotz et al [15]. 21 patients entered the study.…”

Section: Combination Of Systemic Inf Treatment and Monochemotherapymentioning

confidence: 99%

Systemic Treatment of Hepatocellular Carcinoma

Treiber¹

2001

Dig Dis

View full text Add to dashboard Cite

Systemic treatment for hepatocellular carcinoma is indicated in locally advanced or metastatic disease. Monochemotherapies have yielded unsatisfactory results with response rates of around 20% but survival is often not improved. Polychemotherapies may induce complete responses but have substantial toxicity and are limited to selected patients with preserved liver function. Hormonal treatment with tamoxifen is ineffective while megestrol has shown an improvement in quality of life. Octreotide can be given even in cases of impaired liver function, has also a favorable side effect profile and can lead to disease stabilization. Adjuvant therapy with interferon is indicated after successful liver resection or transplantation in patients with chronic viral hepatitis, the role of interferon in other indications or in combination with chemotherapy remains to be determined.

show abstract

Section: Combination Of Systemic Inf Treatment and Monochemotherapymentioning

confidence: 99%

Systemic Treatment of Hepatocellular Carcinoma

Treiber¹

2001

Dig Dis

View full text Add to dashboard Cite

show abstract

Hepatocellular carcinoma

Falkson¹,

Falkson²,

Garbers³

1998

Cancer Treatment and Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer, which is the second leading cause of cancer related deaths globally and has an incidence of 850,000 new cases per year. The main risk factors for developing HCC are wellknown and include infection with hepatitis B and C viruses, alcohol intake and ingestion of the fungal metabolite aflatoxin B1. Nonetheless, knowledge is emerging regarding additional risk factors such as non-alcoholic steatohepatitis. Advances in the understanding of the molecular pathogenesis of HCC led to identification of critical driver mutations, however the most prevalent of these are not yet druggable targets. The molecular classification of HCC is not established, and the Barcelona-Clinic-Liver Cancer Classification is the main clinical algorithm for the stratification of patients according to prognosis and treatment allocation. Surveillance programmes enable detection of early-stage tumours that are amenable to curative therapies-resection, liver transplantation or local ablation. At more-developed stages, only chemoembolization (for intermediate HCC) and sorafenib (for advanced HCC) have shown survival benefits. There are major unmet needs in HCC management that might be addressed through discovery of new therapies and their combinations for use in the adjuvant setting and for intermediate and advanced stage disease, biomarkers for therapy stratification, patient-tailored strategies targeting driver mutations and/or activating signalling cascades and validated measurements of quality of life. Recent failures in testing systemic drugs for intermediate and advanced stages have pointed towards a refinement in trial design and defining novel approaches.

show abstract